WO2022030032A1 - 質量分析装置の機差補正方法 - Google Patents
質量分析装置の機差補正方法 Download PDFInfo
- Publication number
- WO2022030032A1 WO2022030032A1 PCT/JP2021/000235 JP2021000235W WO2022030032A1 WO 2022030032 A1 WO2022030032 A1 WO 2022030032A1 JP 2021000235 W JP2021000235 W JP 2021000235W WO 2022030032 A1 WO2022030032 A1 WO 2022030032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- correction
- peak intensity
- intensity ratio
- signal peak
- value
- Prior art date
Links
- 238000012937 correction Methods 0.000 title claims abstract description 269
- 238000000034 method Methods 0.000 title claims abstract description 77
- 238000004949 mass spectrometry Methods 0.000 title claims abstract description 50
- 239000000126 substance Substances 0.000 claims abstract description 193
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 238000000691 measurement method Methods 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 238000004364 calculation method Methods 0.000 claims description 23
- 239000013076 target substance Substances 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 13
- 230000001131 transforming effect Effects 0.000 claims description 8
- 102000002068 Glycopeptides Human genes 0.000 claims description 5
- 108010015899 Glycopeptides Proteins 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 239000012491 analyte Substances 0.000 abstract 5
- 239000000523 sample Substances 0.000 description 86
- 238000005259 measurement Methods 0.000 description 52
- 239000000243 solution Substances 0.000 description 30
- 238000001114 immunoprecipitation Methods 0.000 description 28
- 239000011159 matrix material Substances 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000012001 immunoprecipitation mass spectrometry Methods 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 19
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 18
- 238000012417 linear regression Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000003795 desorption Methods 0.000 description 10
- 230000006866 deterioration Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 6
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GQLPWHMYJOSZCR-UHFFFAOYSA-N (diphosphonoamino)phosphonic acid Chemical compound OP(O)(=O)N(P(O)(O)=O)P(O)(O)=O GQLPWHMYJOSZCR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XYJLPCAKKYOLGU-UHFFFAOYSA-N 2-phosphonoethylphosphonic acid Chemical compound OP(O)(=O)CCP(O)(O)=O XYJLPCAKKYOLGU-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- UEDATVNCOAQXRQ-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)CP(O)(O)=O.C1(=CC=CC2=CC=CC=C12)CP(O)(O)=O Chemical compound C1(=CC=CC2=CC=CC=C12)CP(O)(O)=O.C1(=CC=CC2=CC=CC=C12)CP(O)(O)=O UEDATVNCOAQXRQ-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 101500024730 Homo sapiens Angiotensin-2 Proteins 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101500024079 Homo sapiens Corticotropin Chemical group 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- NMNFDTCOWIDEAV-UHFFFAOYSA-N OP(O)=O.OP(O)=O Chemical compound OP(O)=O.OP(O)=O NMNFDTCOWIDEAV-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YRZBVIGIGZTWGT-UHFFFAOYSA-N [2-(diphosphonoamino)ethyl-phosphonoamino]phosphonic acid Chemical compound OP(O)(=O)N(P(O)(O)=O)CCN(P(O)(O)=O)P(O)(O)=O YRZBVIGIGZTWGT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GOFLNFPIFZZLIP-UHFFFAOYSA-N ethanol;2,2,2-trifluoroacetic acid Chemical compound CCO.OC(=O)C(F)(F)F GOFLNFPIFZZLIP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- UHNSRFWQBVXBSK-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid Chemical compound OC.OC(=O)C(F)(F)F UHNSRFWQBVXBSK-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- LYRAVEOMIYGVSP-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O.CP(O)(O)=O LYRAVEOMIYGVSP-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- DTSWMPOYOLBKHE-UHFFFAOYSA-N phenylphosphonic acid Chemical compound OP(O)(=O)C1=CC=CC=C1.OP(O)(=O)C1=CC=CC=C1 DTSWMPOYOLBKHE-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
Definitions
- the present invention relates to a method using a peptide ratio obtained by mass spectrometry.
- the present invention relates to a method for correcting a machine difference of a mass spectrometer and a system for correcting a machine difference of a mass spectrometer.
- Non-Patent Documents 1, 2, and 3 the method that uses the intensity ratio of the two signal peaks is most often used. For example, a certain amount of internal standard substance is added to the sample to be compared, pretreatment is performed if necessary, and then mass spectrometry is performed on the sample to determine the intensity ratio of the peak to be measured to the peak of the internal standard substance. The calculated values are compared (Non-Patent Documents 1, 2, and 3).
- patent documents include international publication WO2015 / 178398 (US publication US 2017/0184573), international publication WO2017 / 047529 (US publication US 2018/02389909), and the like.
- a calibration curve of the peak intensity ratio of the standard product to the standard product is prepared by measuring a sample in which a standard product having a constant concentration and a standard product shaken to different concentrations are measured. Absolute quantification of the target substance can be performed by this calibration curve. Therefore, if a calibration curve is created for each device and each measurement, even if there is a difference in the peak intensity ratio between different devices, the unknown target substance existing in the biological sample can be quantified without being affected by it.
- this calibration curve method requires a standard product. If it is not possible to easily synthesize a standard product, or if it is difficult in terms of time and cost to prepare and control the quality of all standard products due to the huge variety of target substances, or if the standard product is unstable, It is not possible to create a calibration curve. As mentioned above, since the peak intensity ratio changes between aircraft in the mass spectrometer, if it is not possible to create a calibration curve, it is necessary to measure the sample to be compared with one aircraft, but it is still detected by using the aircraft. It is difficult to obtain consistent data because the peak intensity ratio fluctuates due to deterioration of the device.
- An object of the present invention is to provide a method for correcting a difference in mass spectrometry data depending on the body of the mass spectrometer, and a system for correcting the difference in the mass spectrometer.
- the present invention includes the following inventions.
- a method for correcting the difference in signal intensity ratio in mass spectrometry including.
- the present invention further includes the following inventions.
- a measurement method creation unit that creates a calibrant measurement method for calculating correction values in a mass spectrometer, and a measurement method creation unit.
- a correction value calculation unit that analyzes the mass spectrometry data acquired using the measurement method and calculates the correction value,
- the machine difference correction system of the mass spectrometer including.
- the peak intensity ratio of the substance to be analyzed can be corrected by using the correction formula obtained from the measurement result of the calibrated substance. As a result, even if the same sample is measured by different aircraft, it is possible to obtain the same peak intensity ratio.
- IP immunoprecipitation
- Sample No. 1 After immunoprecipitation (IP) of a plasma sample (Sample No. 1) spiked with an internal standard peptide (SIL-A ⁇ 1-38), A ⁇ and A ⁇ -related peptides were subjected to three mass spectrometers (Performance 1, 2 and 3). The result measured in is shown.
- the vertical axis of FIG. 1 (A) shows the peak intensity ratio of each of A ⁇ or A ⁇ -related peptides to SIL-A ⁇ 1-38.
- the vertical axis of FIG. 1B shows the peak intensity ratio of each of A ⁇ , A ⁇ -related peptide, or SIL-A ⁇ 1-38 to APP669-711.
- the coefficient of variation (CV) between the devices of each peak intensity ratio measured by three mass spectrometers (Performance 1, 2 and 3) after IP of the plasma sample (Sample No. 1) is shown on the vertical axis.
- the horizontal axis shows the average value measured by three mass spectrometers.
- the vertical axis shows the logarithmic conversion value of each peak intensity ratio measured by Performance 1 (standard device) after IP of the plasma sample (Sample No. 1).
- the value obtained by logarithmically converting each peak intensity ratio measured by Performance 2 or 3 of the same sample is shown on the horizontal axis.
- the linear regression equation of the measured value of Performance 2 or 3 with respect to the measured value of Performance 1 (standard instrument) and the coefficient of determination (R 2 ) are shown in the figure.
- the vertical axis shows each peak intensity ratio measured by Performance 1 (standard device) after IP of a plasma sample (Sample No. 1).
- each peak intensity ratio of the same sample measured by Performance 2 or 3 is shown on the horizontal axis.
- the power approximation formula of the measured value of Performance 2 or 3 with respect to the measured value of Performance 1 (standard device) and the coefficient of determination (R 2 ) are shown in the figure.
- the peak intensity ratio of A ⁇ or A ⁇ -related peptide to the internal standard peptide (SIL-A ⁇ 1-38) measured by Performance 2 and Performance 3 was set to the same peak intensity ratio as Performance 1 (standard device).
- the corrected value is shown in.
- the vertical axis of FIG. 5 shows the peak intensity ratio of each of A ⁇ or A ⁇ -related peptides to SIL-A ⁇ 1-38.
- the numerical value (%) in FIG. 5 indicates the coefficient of variation (CV) of the peak intensity ratio in Performance 1 (standard device), Performance 2 (Cal.) And Performance 3 (Cal.).
- FIG. 6A shows the peak intensity ratio of A ⁇ or A ⁇ -related peptide to SIL-A ⁇ 1-38 measured by Performance 2 and Performance 3 before correction using the correction formula, and is shown in FIG. 6 (A).
- B) shows the corrected peak intensity ratio.
- Performance 2 (Cal.) And Performance 3 (Cal.) Mean the calibrated value.
- the numerical values (%) in FIGS. 6 (A) and 6 (B) indicate the coefficient of variation (CV) of the peak intensity ratio in Performance 1 (standard device), Performance 2 (Cal.) And Performance 3 (Cal.).
- FIG. 7A shows the peak intensity ratio of A ⁇ or A ⁇ -related peptide to SIL-A ⁇ 1-38 measured by Performance 2 and Performance 3 before correction using the correction formula, and is shown in FIG. 7 (A).
- B) shows the corrected peak intensity ratio.
- Performance 2 (Cal.) And Performance 3 (Cal.) Mean the calibrated value.
- the numerical values (%) in FIGS. 7 (A) and 7 (B) indicate the coefficient of variation (CV) of the peak intensity ratio in Performance 1 (standard device), Performance 2 (Cal.) And Performance 3 (Cal.).
- the results of performing IP-MS on plasma samples (Sample No. 1) divided into two days (Day 1 and Day 2) are shown.
- the vertical axis shows the logarithmically converted value of each peak intensity ratio measured by Performance 1 (standard instrument) on each day.
- the value obtained by logarithmically converting each peak intensity ratio measured by Performance 2 is shown on the horizontal axis.
- the linear regression equation of the measured value of Performance 2 with respect to the measured value of Performance 1 and the coefficient of determination (R 2 ) are shown in the figure.
- the results of performing IP-MS on plasma samples (Sample No. 1) divided into two days (Day 1 and Day 2) are shown.
- the vertical axis shows the logarithmically converted value of each peak intensity ratio measured by Performance 1 (standard instrument) on each day.
- FIG. 10A shows the results of Performance Unit 1 (before the detector is replaced), FIG.
- FIG. 10B shows the results of Performance Unit 1 (after the detector is replaced), and FIG. 10C shows the results of Performance Unit 3.
- the peak intensity ratio of each of A ⁇ or A ⁇ -related peptides to SIL-A ⁇ 1-38 acquired by IP-MS under the three conditions of Performance No. 1 and Performance No. 3 before and after the detection of the detector is shown.
- FIG. 11A shows the peak intensity ratio of A ⁇ or A ⁇ -related peptide to SIL-A ⁇ 1-38 before the correction formula is used
- FIG. 12A shows the peak intensity ratio before the correction formula is used to correct the peak intensity ratio of the biomarker
- FIG. 12B shows the peak intensity ratio after the correction.
- the peak intensity ratio of each of A ⁇ or A ⁇ -related peptides to SIL-A ⁇ 1-38 acquired by IP-MS under the three conditions of Performance No. 1 and Performance No. 3 before and after the detection of the detector is shown.
- FIG. 13 (A) shows the peak intensity ratio before correcting the peak intensity ratio of A ⁇ or A ⁇ -related peptide to SIL-A ⁇ 1-38 using the correction formula
- FIG. 13 (B) shows the peak intensity ratio after correction. Is shown. It was corrected by a method using a value and b value.
- FIG. 14A shows the peak intensity ratio before the correction using the correction formula
- FIG. 14B shows the peak intensity ratio after the correction. It was corrected by a method using a value and b value.
- One embodiment of the method of the present invention is a method for correcting a difference in signal intensity ratio in mass spectrometry.
- the substance to be analyzed is not particularly limited, and may include, for example, peptides, glycopeptides, sugar chains, proteins, lipids, glycolipids and the like. Peptides, glycopeptides, sugar chains, proteins, lipids and glycolipids can include various. More specifically, it may be A ⁇ and A ⁇ -related peptides. "A ⁇ and A ⁇ -related peptides” may be simply collectively referred to as "A ⁇ -related peptides”. "A ⁇ and A ⁇ -related peptides" include peptides containing at least a part of the sequences of A ⁇ and A ⁇ produced by cleavage of amyloid precursor protein (APP). In the examples, examples using A ⁇ and A ⁇ -related peptides are shown.
- APP amyloid precursor protein
- the peptide may be a peptide obtained by immunoprecipitation (IP).
- IP immunoprecipitation
- it may be a peptide produced by digestion of a protein with an enzyme such as peptidase, or a peptide fractionated by chromatography.
- the substance to be analyzed may include an internal standard substance.
- the internal standard substance can be appropriately selected by those skilled in the art.
- stable isotope-labeled substances may be used.
- a stable isotope-labeled substance may be used for one of the substances to be analyzed.
- a ⁇ 1-38 (SIL-A ⁇ 1-38) labeled with a stable isotope as an internal standard substance is shown.
- SIL is stable isotope-labeled.
- a sample containing the substance to be analyzed is subjected to mass spectrometry.
- the sample to be subjected to mass spectrometry is not particularly limited, but may be, for example, a biological sample.
- Biogenic samples include blood, cerebrospinal fluid (CSF), urine, body fluids such as saliva, and sputum; and feces.
- Blood samples include whole blood, plasma, serum and the like. Blood samples can be prepared by appropriately treating whole blood collected from an individual. The treatment performed when preparing a blood sample from the collected whole blood is not particularly limited, and any clinically acceptable treatment may be performed. For example, centrifugation can be performed.
- the blood sample to be subjected to mass spectrometry may be one that has been appropriately stored at a low temperature such as freezing in the middle stage of the preparation step or the post-step of the preparation step.
- a biological sample such as a blood sample is subjected to mass spectrometry
- the biological sample is discarded without being returned to the original subject.
- the sample to be subjected to mass spectrometry may be a sample after various pretreatments have been performed. For example, it may be after performing an immunoprecipitation method (IP). It may be after digestion of the protein by an enzyme such as peptidase. It may be after chromatography. As the sample to be subjected to mass spectrometry, a sample to which a certain amount of an internal standard substance is added may be used.
- IP immunoprecipitation method
- the eluate obtained by the immunoprecipitation method may be subjected to mass spectrometry (immunoprecipitation-mass spectrometry; IP-MS).
- the immunoprecipitation method is performed using an antibody-immobilized carrier prepared using an immunoglobulin having an antigen-binding site that can recognize the substance to be analyzed or an immunoglobulin fragment containing an antigen-binding site that can recognize the substance to be analyzed. You may.
- immunoprecipitation may be continuously performed, and then the peptide in the sample may be detected by a mass spectrometer (cIP-MS).
- cIP-MS mass spectrometer
- the mass spectrometric method is not particularly limited, and includes a mass spectrometric method such as a matrix-assisted laser desorption / ionization (MALDI) mass spectrometric method and an electrospray ionization (ESI) mass spectrometric method.
- a mass spectrometric method such as a matrix-assisted laser desorption / ionization (MALDI) mass spectrometric method and an electrospray ionization (ESI) mass spectrometric method.
- MALDI-TOF matrix-assisted laser desorption / ionization-flying time
- MALDI-IT matrix-assisted laser desorption / ionization-ion trap
- MALDI-IT-TOF matrix-assisted laser desorption / ionization
- Deionization-ion trap-flight time type mass analyzer MALDI-FTICR (matrix-assisted laser desorption ionization-Fourier conversion ion cyclotron resonance) type mass analyzer, ESI-QqQ (electrospray ionization-triple quadrupole) Use a type mass analyzer, ESI-Qq-TOF (electrospray ionization-tandem quadrupole-flight time) type mass analyzer, ESI-FTICR (electrospray ionization-Fourier conversion ion cyclotron resonance) type mass analyzer, etc. Can be done.
- a person skilled in the art can appropriately determine the matrix and the matrix solvent according to the substance to be analyzed.
- ⁇ -cyano-4-hydroxycinnamic acid CHCA
- 2,5-dihydroxybenzoic acid 2,5-DHB
- sinapic acid 3-aminoquinoline (3-AQ) and the like are used. Can be done.
- the matrix solvent for example, it can be selected from the group consisting of acetonitrile (ACN), trifluoroacetic acid (TFA), methanol, ethanol and water. More specifically, an ACN-TFA aqueous solution, an ACN aqueous solution, a methanol-TFA aqueous solution, a methanol aqueous solution, an ethanol-TFA aqueous solution, an ethanol solution and the like can be used.
- the concentration of ACN in the ACN-TFA aqueous solution can be, for example, 10 to 90% by volume, and the concentration of TFA can be, for example, 0.05 to 1% by volume, preferably 0.05 to 0.1% by volume.
- the matrix concentration can be, for example, 0.1-50 mg / mL, preferably 0.1-20 mg / mL, or 0.3-20 mg / mL, more preferably 0.5-10 mg / mL.
- a matrix additive (comatrix) in combination.
- the matrix additive can be appropriately selected by those skilled in the art depending on the analysis target (polypeptide) and / or the matrix.
- a phosphonic acid group-containing compound can be used as the matrix additive.
- phosphonic acid Phosphonic acid
- methylphosphonic acid Metalphosphonic acid
- phenylphosphonic acid Phenylphosphonic acid
- 1-naphthylmethylphosphonic acid (1-Naphthylmethylphosphonic acid
- a compound containing two or more phosphonic acid groups methylenediphosphonic acid (MDPNA), Ethylenediphosphonic acid, ethane-1-hydroxy-1,1-diphosphonic acid (Ethane-1-). Hydroxy-1,1-diphosphonic acid), Nitrilotriphosphonic acid, Ethylenediaminetetraphosphonic acid and the like.
- MDPNA methylenediphosphonic acid
- Ethane-1- ethane-1-hydroxy-1,1-diphosphonic acid
- Hydroxy-1,1-diphosphonic acid Hydroxy-1,1-diphosphonic acid
- Nitrilotriphosphonic acid Nitrilotriphosphonic acid
- Ethylenediaminetetraphosphonic acid Ethylenediaminetetraphosphonic acid and the like.
- phosphonic acid group-containing compounds a compound having 2 or more, preferably 2 to 4 phosphonic acid groups in one molecule is preferable.
- the use of the phosphonic acid group-containing compound is useful, for example, when the metal ions of the washing solution remaining on the surface of the antibody-immobilized carrier are mixed in the eluate after the dissociation step. This metal ion adversely affects the background in mass spectrometry.
- the use of a phosphonic acid group-containing compound has the effect of suppressing such adverse effects.
- additives for example, substances selected from the group consisting of ammonium salts and organic bases may be used.
- the matrix additive can be prepared in water or in a matrix solvent in a solution of 0.1 to 10 w / v%, preferably 0.2 to 4 w / v%.
- the matrix additive solution and the matrix solution can be mixed, for example, in a volume ratio of 1: 100 to 100: 1, preferably 1:10 to 10: 1.
- calibration substance In this embodiment, two or more calibration substances are measured by a mass spectrometer. The correction formula in the mass spectrometer is calculated using the measurement result of the calibration substance.
- the calibration substance can be appropriately determined by those skilled in the art.
- the substance to be analyzed may be used itself, or a substance different from the substance to be analyzed may be used.
- a stable isotope-labeled substance may be used.
- Stable isotope-labeled substances and non-stable isotope-labeled substances may be used.
- a ⁇ and A ⁇ -related peptides may be used as the calibration substance.
- a ⁇ 1-38 SIL-A ⁇ 1-38 labeled with a stable isotope may be used as one of the calibration substances.
- the calibration substance may contain one compound and a compound labeled with a stable isotope.
- a compound is ionized and detected.
- the ionization efficiency differs depending on the compound, and the difference in the ionization efficiency affects the mass spectrometric measurement result.
- a compound and a compound labeled with a stable isotope have the same ionization efficiency. Therefore, by using these as a calibration substance, a more accurate correction formula can be obtained.
- a ⁇ 1-38 and A ⁇ 1-38 (SIL-A ⁇ 1-38) labeled with a stable isotope are used as calibration substances.
- Calibrant is a solution containing a calibration substance.
- the calibrant is a solution containing two or more calibration substances.
- the sample itself containing the substance to be analyzed can be used. Further, it is also possible to use a sample in which the calibration substance is added to the sample itself containing the substance to be analyzed. A solution containing two or more calibration substances may be prepared and used separately from the sample itself containing the substance to be analyzed.
- the correction formula in the mass spectrometer is calculated. Multiple data are required to calculate the correction formula. For example, when calculating the correction formula using the signal peak intensity ratio, a plurality of data having different signal peak intensity ratios are required.
- the ratio of the signal peak intensities of the other two or more calibration substances to the signal peak intensities of one calibration substance may be calculated respectively to obtain two or more signal peak intensity ratios.
- the peak intensity ratios of C2 / C1 and C3 / C1 are calculated with reference to C1.
- a plurality of calibrants having different concentrations of the calibration substance for which the signal peak intensity ratio should be obtained may be used.
- the ratio of the signal peak intensity of one calibration substance to the signal peak intensity of another calibration substance may be calculated for each calibrant to obtain two or more signal peak intensity ratios.
- the peak intensity ratio of C2 / C1 is calculated for each of a plurality of calibrants having different concentrations.
- a plurality of calibrants may be used in which the concentration of one calibration substance is constant and the concentration of another calibration substance is changed.
- the concentration ratio of the calibration substance for which the signal peak intensity ratio should be calculated in the plurality of calibrants may be, for example, in the range of 1/4 to 4.
- five types of calibrant solutions adjusted to have a concentration ratio of 1/4, 1/2, 1, 2, and 4 can also be used.
- the correction formula in the mass spectrometer is calculated using the results of measuring two or more calibration substances with the mass spectrometer. Then, the calculated correction formula is used to correct the measurement result of the substance to be analyzed.
- the method of correction in the present invention includes a method of correction using a correction formula with a standard device. It also includes a method of standardizing measurement results in mass spectrometry using a calibration material whose abundance is known.
- the correction formula is calculated for each mass spectrometer. Even with the same mass spectrometer, it is preferable to calculate a new correction formula when parts such as the detector are replaced or when the device settings such as the detector voltage are changed. Further, the correction formula may be calculated periodically. As a result, it is possible to detect deterioration or failure of the detector or the like of the mass spectrometer and obtain a measurement result excluding the influence thereof. Therefore, regardless of the body and conditions of the mass spectrometer, it is possible to accurately compare and evaluate the abundance ratio of the substance to be analyzed among a plurality of samples.
- the calibration substance is measured under the same device conditions as the device condition for the measurement, and the correction formula is calculated.
- the correction formula under the same conditions as the measurement of the substance to be analyzed can be used, and the accuracy of the correction is further improved. Therefore, regardless of the body and conditions of the mass spectrometer, it is possible to more accurately compare and evaluate the abundance ratio of the substance to be analyzed among a plurality of samples.
- the calibrant solution containing the two or more calibration substances is measured, and the signal peak intensity of each calibration substance is obtained.
- the ratio of the signal peak intensity of one or more other calibration substances to the signal peak intensity of one calibration substance is calculated respectively.
- a known method such as the least squares method may be appropriately used for calculating the regression equation.
- the logarithm of the signal peak intensity ratio may be used to calculate the regression equation.
- the regression equation may be appropriately selected from linear, polynomial, exponential, logarithmic, or exponentiation.
- a linear regression equation can be calculated using a value obtained by logarithmically transforming the signal peak intensity ratio.
- a power regression equation can be calculated using the signal peak intensity ratio. The calculated regression equation is used as the correction equation of the mass spectrometer.
- the signal peak intensity ratio in the mass spectrometer for which the correction formula should be calculated is x
- the signal peak intensity ratio in the standard is y.
- the sample containing the substance to be analyzed is measured, and the signal peak intensity of the substance to be analyzed is obtained.
- the ratio of the signal peak intensity of the other substance to be analyzed to the signal peak intensity of the substance to be analyzed as the reference is calculated.
- the calculated signal peak intensity ratio is shown in 5-1-1. Correct using the correction formula calculated in.
- the corrected signal peak intensity ratio is the value at which the difference between the standard and the aircraft is cancelled. That is, the value is equivalent to the signal peak intensity ratio obtained when measured with a standard device. Therefore, if the corrected signal peak intensity ratio is used, the signal peak intensity ratio of the substance to be analyzed, that is, the abundance ratio of the substance to be analyzed can be compared and evaluated among a plurality of samples regardless of the body of the mass spectrometer. It is possible.
- a correction formula for normalizing the signal peak intensity ratio can be calculated using a plurality of calibrant solutions in which the concentration ratios of the two calibration substances are known.
- a plurality of calibrant solutions for which the concentration ratios of the two calibration substances are known.
- a plurality of solutions in which one calibration substance is present at a constant concentration and the concentration of the other calibration substance is different may be used.
- SIL-A ⁇ 1-38 has a constant concentration and A ⁇ 1-38 has a concentration ratio of 1 / 4,1 / 2,1,2,4 to SIL-A ⁇ 1-38. May be good.
- IC intensity ratio calibrant
- a regression equation is calculated between the known concentration ratios of the two calibration substances in each calibrant solution and the signal peak intensity ratio calculated above.
- a known method such as the least squares method may be appropriately used for calculating the regression equation.
- the logarithm of the signal peak intensity ratio may be used to calculate the regression equation.
- the regression equation may be appropriately selected from linear, polynomial, exponential, logarithmic, or exponentiation.
- a linear regression equation can be calculated using the logarithm of the signal peak intensity ratio.
- a power regression equation can be calculated using the signal peak intensity ratio. The calculated regression equation is used as the correction equation of the mass spectrometer.
- the calculated signal peak intensity ratio is shown in the above 5-2-1. Correct using the correction formula calculated in.
- the signal peak intensity ratio of the substance to be analyzed is converted into the signal peak intensity ratio standardized by the calibration substance.
- the difference in the obtained standardized signal peak intensity due to the aircraft is canceled by the correction formula. Therefore, it is possible to compare and evaluate the abundance ratio of the substance to be analyzed among a plurality of samples regardless of the body of the mass spectrometer. That is, it will be possible to directly compare the mass spectrometric measurement results not only in Japan but also in the United States, France and other countries.
- this correction can be applied to research and inspection using various mass spectrometry, and is a highly versatile technique.
- the correction formula differs depending on the mass spectrometer. Even with the same mass spectrometer, if parts such as the detector are replaced or if the device settings such as the detector voltage are changed, the state of the mass spectrometer will be different, so it depends on the state of the device. , Each correction formula is different. Further, the correction formula may change even when the state of the device changes due to deterioration of the detector or the like.
- the signal peak intensity ratio detected by the mass spectrometer becomes large when the same sample is measured. It is considered that this is because the signal peak of the calibrant substance having a small abundance becomes smaller due to the influence of the device conditions such as deterioration of the detector.
- the signal peak intensity becomes too small, the measurement accuracy generally decreases from the viewpoint of the S / N ratio. Therefore, in the mass spectrometer, it is preferable that the signal peak intensity does not become too small.
- the correction value b value in the correction equation becomes large when the signal peak intensity detected by the mass spectrometer becomes small due to the influence of some device condition. Therefore, if the b value is set to a certain range, the signal peak intensity does not become too small, the measurement accuracy by the mass spectrometer is further improved, and the correction accuracy is further improved.
- the b value can be changed by changing the detection sensitivity of the mass spectrometer.
- the b value can be controlled, for example, by changing the detector voltage. Further, for example, the b value can be changed by changing the baseline level of the Analog digital (AD) converter.
- AD Analog digital
- the abundance ratio of the substance to be analyzed among a plurality of samples can be determined regardless of the body of the mass spectrometer or the device conditions. It is possible to make a comparative evaluation. Further, by adjusting the device conditions so that the value of the correction coefficient in the correction formula is within a certain range, the signal peak intensity ratio of the substance to be analyzed can be corrected more accurately.
- the machine difference correction system of the mass spectrometer is A measurement method creation unit that creates a calibrant measurement method for calculating correction values in a mass spectrometer, and a measurement method creation unit.
- a correction value calculation unit that analyzes the mass spectrometry data acquired using the measurement method and calculates the correction value, including.
- the program for correcting the difference in the mass spectrometer can be applied to the computer.
- a measurement method creation step to create a measurement method for measuring a sample for calculating a correction value in a mass spectrometer, and a measurement method creation step.
- FIG. 20 is a schematic block diagram of the correction value calculation system of the mass spectrometer of the present embodiment.
- a mass spectrometry unit 1 that executes measurement on a sample
- a data processing unit 2 that performs data processing before and after measurement execution
- an input unit 3 and a display unit 4 that are user interfaces
- the data processing unit 2 analyzes the measurement method creation unit 20 that creates a measurement method for measuring the sample for calculating the correction value in the mass spectrometry unit 1 and the mass spectrum data obtained by the mass spectrometry unit 1.
- the correction value calculation unit 21 for calculating the correction value is included.
- the mass spectrometric unit 1 is not particularly limited, but includes a mass spectrometric method such as a matrix-assisted laser desorption / ionization (MALDI) mass spectrometric method and an electrospray ionization (ESI) mass spectrometric method.
- a mass spectrometric method such as a matrix-assisted laser desorption / ionization (MALDI) mass spectrometric method and an electrospray ionization (ESI) mass spectrometric method.
- MALDI-TOF matrix-assisted laser desorption / ionization-flying time
- MALDI-IT matrix-assisted laser desorption / ionization-ion trap
- MALDI-IT-TOF matrix-assisted laser desorption / ionization
- Deionization-ion trap-flight time type mass analyzer MALDI-FTICR (matrix-assisted laser desorption ionization-Fourier conversion ion cyclotron resonance) type mass analyzer, ESI-QqQ (electrospray ionization-triple quadrupole) Use a type mass analyzer, ESI-Qq-TOF (electrospray ionization-tandem quadrupole-flight time) type mass analyzer, ESI-FTICR (electrospray ionization-Fourier conversion ion cyclotron resonance) type mass analyzer, etc. Can be done.
- the actual state of the data processing unit 2 is, for example, a general-purpose personal computer or a higher-performance workstation. It may be a single unit or a computer system consisting of a plurality of units. The present embodiment is achieved by installing a dedicated data processing program on such a computer and operating the computer. Further, usually, the input unit 3 is a pointing device such as a keyboard and a mouse attached to the computer. Further, the display unit 4 is usually a monitor attached to a computer.
- the mass spectrometer may have different measurement results depending on the aircraft and device conditions, even if the same sample is measured. In order to cancel the difference due to the aircraft and equipment conditions, 5-2. Make corrections as described in.
- the measurement method creation unit 20 automatically creates a calibrant measurement method for calculating a correction value. According to the measurement method created by the measurement method creation unit 20, the mass spectrometry unit 1 measures the sample.
- the measurement method creation unit 20 further includes a setting unit 201.
- the setting unit 201 sets the laser power value used for the measurement of the calibrant.
- the correction value calculation unit 21 analyzes the mass spectrum data measured by the mass spectrometry unit 1 and calculates the correction value using the signal peak intensity ratio.
- FIG. 21 is a flowchart showing a procedure for calculating a correction value of the mass spectrometer.
- the user prepares a sample to be used for calculating the correction value of the mass spectrometer.
- a sample five types of samples (IC1 to IC5) in which the ratio of the concentration of the internal standard substance and the concentration of the target substance are gradually different are used.
- the concentration ratio concentration of internal standard substance: concentration of target substance
- IC-2 1 2, IC-3 1: 1, IC-4 1 : 0.5
- IC-5 is 1: 0.25.
- FIG. 22 shows an example of the graphical user interface (GUI) displayed on the display unit 4 when the measurement method is created.
- GUI graphical user interface
- the GUI includes a data set name input unit and a sample plate display unit. The user inputs the data set name by the operation through the input unit 5 and presses the file creation button (S1).
- the measurement method creation unit 20 creates a measurement method for the input data set name (S2, measurement method creation step). Specifically, the laser power value is calculated in advance in order to set the laser power value of the mass spectrometer used in the measurement method. Further, the sample dropping position of each sample IC 1 to 5 is determined. The measurement method creation unit 20 displays the laser power on the GUI displayed on the display unit 4, and displays the sample dropping positions of the ICs 1 to 5 on the sample plate display unit of the GUI.
- the laser power can be calculated by various known methods.
- n is an integer of 3 or more
- a straight line connecting two plot points adjacent to each other in the laser power axis direction For each plot point, the index value that reflects the ratio of the forward tilt value, which is the slope of the straight line on the front side, to the backward tilt value, which is the slope of the straight line on the rear side, is calculated, and the index value is obtained.
- a method of adjusting the laser power can be used, which has a processing step of selecting an appropriate laser power using the above.
- the calculated laser power may have a different value depending on the well of the sample plate.
- the laser power calculated for the wells (calibrant wells) into which the sample ICs 1 to 5 measured by this measurement method and used for calculating the correction value are dropped is the wells (samples) used for measuring the actual sample to be analyzed.
- the value may be different from the laser power used in the well).
- the laser power used in the calibrant well may be 10 lower than the laser power used in the sample well.
- the sample dropping position can be determined by various known methods.
- the determined sample dropping position is displayed on the sample plate display unit as illustrated in FIG. 22.
- it can be determined to drop IC-1, IC-2, IC-3, IC-4, and IC-5 from the right end of the uppermost stage.
- the user drops each calibrant IC 1 to 5 at the sample dropping position indicated on the display unit 4, and starts the measurement.
- the mass spectrometric unit 1 measures each calibrant under predetermined conditions (S3).
- FIG. 23 shows an example of the graphical user interface (GUI) displayed on the display unit 4 when the correction value is calculated.
- GUI graphical user interface
- the correction value calculation unit 21 analyzes the mass spectrum data measured by the mass spectrometry unit 1 under the selected data set name (S4), and calculates the correction value (S5).
- the correction value calculation step includes S4 and S5.
- S4 and S5. For the calculation of the correction value, for example, the above-mentioned [5. Correction of measurement results in a mass spectrometer] can be used.
- the ratio of the signal peak intensity of the target substance to the signal peak intensity of the internal standard substance in each of the sample ICs 1 to 5 is calculated.
- the calculated correction coefficient b of the regression equation is output as the correction value b value.
- the correction value b value is displayed on the GUI of the display unit 4.
- the user measures the sample to be analyzed by the mass spectrometry unit 1 and obtains the measurement result corrected by using the b value.
- the peak intensity ratio obtained for each aircraft was corrected using the regression equation. With this correction, it became possible to obtain the same peak intensity ratio even if the same sample was measured on different aircraft. It also has the effect of correcting the peak intensity ratio that fluctuates due to replacement of the detector, voltage change, and deterioration. It is not necessary to prepare a stable isotope substance for each target substance, and it is possible to compare and evaluate the amount of the target substance with one type of stable isotope substance.
- This method can be used not only for peptides obtained by IP, but also for peptides produced by digestion of proteins with enzymes such as peptidase, and peptides fractionated by chromatography. It can also be used not only for peptides but also for glycopeptides, sugar chains, and lipids.
- Example 1 Correction method for aligning the peak intensity ratio in one device]
- Example 1-1 Measurement of plasma A ⁇ and A ⁇ -related peptides]
- the A ⁇ and A ⁇ -related peptides to be analyzed in this example were prepared as follows.
- IP-MS Immunoprecipitation-mass spectrometry
- the IP was carried out as follows. Antibodies immobilized with anti-A ⁇ monoclonal antibodies (clones 6E10 and 4G8) immobilized on magnetic beads with OTG-glycine buffer (1% n-Octyl- ⁇ -D-thioglucoside (OTG), 50 mM glycine, pH 2.8). Washed twice and washed 3 times with 100 ⁇ L of wash buffer. Binding buffer containing 10 pM SIL-A ⁇ 1-38 (AnaSpec, San Jose, CA, USA) in 250 ⁇ L of plasma sample (0.2% (w / v) n-Dodecyl- ⁇ -D-maltoside (DDM), 0.
- OTG-glycine buffer 1% n-Octyl- ⁇ -D-thioglucoside (OTG), 50 mM glycine, pH 2.8. Washed twice and washed 3 times with 100 ⁇ L of wash buffer. Binding buffer containing 10 pM SIL-A ⁇ 1-38 (
- n-Nonyl- ⁇ -D-thiomaltoside 800 mM GlcNAc, 100 mM Tris-HCl, 300 mM NaCl, pH 7.4
- NTM n-Nonyl- ⁇ -D-thiomaltoside
- a ⁇ and A ⁇ -related peptides were captured by incubation at 4 ° C. for 1 hour. Then, it was washed once with a washing buffer (500 ⁇ L or 100 ⁇ L), washed four times with a washing buffer of 100 ⁇ L, and then washed twice with 50 mM ammonium acetate (50 ⁇ L or 20 ⁇ L).
- a ⁇ and A ⁇ -related peptides trapped in the antibody-immobilized beads were eluted with 5 ⁇ L of 70% acetonitrile containing 5 mM hydrochloric acid. 1 ⁇ L of the eluate was added dropwise to 4 wells on the ⁇ Focus MALDI plate TM 900 ⁇ m to which the matrix was added. It was measured with a Linear TOF in positive ion mode using three AXIMA Performances (Shimadzu / KRATOS, Manchester, UK). The mass spectrum was acquired by accumulating 40 shots at each of the 400 points in the raster mode.
- the quantitative value the value obtained by averaging the peak intensity ratios of each A ⁇ and A ⁇ -related peptide to the internal standard peptide (SIL-A ⁇ 1-38) in the spectrum measured at 4 well was used.
- the amino acid sequences of the measured A ⁇ and A ⁇ -related peptides are shown in Table 1.
- FIG. 1 A Comparative analysis of peak intensity ratios between devices.
- the peak intensity ratio of A ⁇ or A ⁇ -related peptide to the internal standard peptide (SIL-A ⁇ 1-38) obtained by IP-MS of plasma sample (Sample 1) is shown in FIG. 1 (A).
- the same sample was measured using three mass spectrometers (Performances 1 to 3) of the same model, and the peak intensity ratios of most A ⁇ and A ⁇ -related peptides were different in all three.
- the coefficient of variation (CV) of A ⁇ 1-40 was 48.7%, and the CV of A ⁇ 1-42 was 54.0%, confirming that the difference between the three units was particularly large.
- the CV of A ⁇ 6-40 was 3.8%, and almost the same result was obtained among the three units.
- a ⁇ 6-40 has a peak intensity ratio close to 1, but A ⁇ 1-40 and A ⁇ 1-42 have a peak intensity ratio far from 1. From this, the closer the peak intensity ratio is to 1, the smaller the difference between the three units, and the farther away from 1 (that is, the smaller or larger than 1), the larger the difference between the three units tends to be. It was suggested that there was.
- Peak intensity ratio of A ⁇ or A ⁇ -related peptide to internal standard peptide measured by three mass spectrometers, and A ⁇ , A ⁇ -related peptide, or SIL-A ⁇ 1-38 to APP669-711.
- the average value of the peak intensity ratio and CV are shown in FIG. As is clear from this figure, the closer the peak intensity ratio is to 1, the smaller the CV between the three units, and the farther the peak intensity ratio is from 1, the larger the CV between the three units.
- Performance 1 When Performance 1 is used as a standard, the peak intensity ratio of A ⁇ or A ⁇ -related peptide to the internal standard peptide (SIL-A ⁇ 1-38) measured by Performance 2 and Performance 3 by using these regression equations can be determined. I decided to investigate whether it can be corrected to the same peak intensity ratio as the standard device (Performance 1).
- the peak intensity ratio measured by Performance 2 and Performance 3 was substituted into x in the above linear regression equation, and correction was performed by obtaining y (FIG. 5).
- the corrected values are represented as Performance 2 (Cal.) And Performance 3 (Cal.), Respectively. As a result, the difference between the three peptides was small for all peptides, and the CV was also low.
- the corrected values were the same regardless of whether the linear regression equation of the logarithmic transformation value was used or the exponentiation equation was used.
- this result shows that the same peak intensity ratio can be obtained by correcting the peak intensity ratio by the correction formula even if the same sample is measured by different mass spectrometers.
- this correction formula shows that it is possible to eliminate the error (machine difference) of the peak intensity ratio caused by the difference in the body of the mass spectrometer.
- the reason why the logarithmic of the peak intensity ratio has a linear relationship between each aircraft is that the secondary electron multiplier (SEM) used in the detector of mass spectrometry exponentially converts the electrical signal of ions. It is considered that a large signal is obtained by amplifying the signal.
- SEM secondary electron multiplier
- Example 2 Method of standardizing and correcting the peak intensity ratio] [2-1 Measurement of plasma A ⁇ and A ⁇ -related peptides]
- the A ⁇ and A ⁇ -related peptides to be analyzed in this example were prepared as follows.
- IP-MS immunoprecipitation
- MS mass spectrometry
- the antibody beads were washed and the A ⁇ -related peptide was eluted using the 1st IP eluate (glycine buffer containing DDM (pH 2.8)). After returning to neutrality with a Tris buffer containing DDM, the antibody beads are once again subjected to an antigen-antibody reaction with the A ⁇ -related peptide (2nd IP), and after washing, the A ⁇ -related peptide is mixed with the 2nd IP eluate (5 mM HCl, 0.1 mM). Elution with Methionine, 70% (v / v) acetonitrile).
- Mass spectrum data was acquired by Linear TOF in positive ion mode using AXIMA Performance (Shimadzu / KRATOS, Manchester, UK).
- the m / z value of Linear TOF is displayed by the average mass of the peak.
- the m / z value was calibrated using human angiotensin II, human ACTH fragment 18-39, bovine insulin oxidized beta-chain, and bovine insulin as external standards.
- the mass spectrum was acquired by accumulating 40 shots at each of the 400 points in the raster mode.
- As the quantitative value the value obtained by averaging the peak intensity ratios of each A ⁇ and A ⁇ -related peptide to the internal standard peptide (SIL-A ⁇ 1-38) in the spectrum measured at 4 well was used.
- IC-1-5 concentrates dilute 10-fold with 2-1 2nd IP eluate (5 mM HCl, 0.1 mM Matrixine, 70% (v / v) acetonitrile) and IC- 1 to 5 were prepared, 0.5 mg / mL CHCA / 0.2% (w / v) MDPNA 0.5 ⁇ L was added dropwise in advance, and 1 ⁇ L of IC-1 to 5 was added onto 900 ⁇ m of dried ⁇ Focus MALDI plate TM . It was dropped into 4 wells and dried.
- the protein / peptide compositions of ICs-1 to 5 are shown in Table 5.
- the amount ratios of A ⁇ 1-38 to SIL-A ⁇ 1-38 in IC-1 to 5 were 4, 2, 1, 1/2, and 1/4, respectively.
- the mass spectrum data of each of IC-1 to 5 was acquired by the same means as in 2-1.
- IP-MS and IC-1-5 measurements of human plasma were performed under the three conditions of Performance Unit 1 and Performance Unit 3 before and after the detection of the detector.
- the a value of the exponentiation equation does not change depending on the state of the airframe, but the b value is greatly affected by the conditions of the airframe, so the a value and b value obtained by IC measurement
- the difference in the peak intensity ratio of A ⁇ or A ⁇ -related peptide to SIL-A ⁇ 1-38 between the three conditions is reduced by the correction by the power approximation formula, and the coefficient of variation (CV) is from 16.8 to 21.5% before correction. After correction, it decreased to 3.9 to 13.6%.
- the difference between the two peak intensities was small and the intensity ratio was close to 1, so no effect was observed for APP669-711 / A ⁇ 1-42, which has a sufficiently small CV, but A ⁇ 1-40, which has a large intensity ratio.
- the CV was 41.1% before the correction and was 8.0% after the correction (FIG. 12).
- this correction method has the effect of reducing the variation in the peak intensity ratio between the devices. Further, since the a value does not change depending on the state of the airframe, it was shown that even when only the b value is used as the correction value, the effect of reducing the variation in the peak intensity ratio between the devices can be obtained. Since the method of the second embodiment is standardized by the power approximation formula, the peak intensity ratio can be applied without the need to use a specific airframe as a standard.
- the b value can be adjusted by the detector voltage.
- the biomarker (APP669-711 / A ⁇ 1) is used when the intensity ratios of A ⁇ 1-40, A ⁇ 1-42, and APP669-766 to the internal standard are read from the obtained mass spectrum and this intensity ratio is not corrected by the b value. -42 and A ⁇ 1-40 / A ⁇ 1-42) were compared.
- FIG. 15 is a comparison before and after the correction of the A ⁇ 1-40 / A ⁇ 1-42 ratio.
- the data before correction has a large variation among three units, and even when the detector voltage is changed by one unit, the variation is large.
- the b value By performing the correction using the b value, it was confirmed that the variation of the three units was suppressed and the peptide ratio was kept constant even when the detector voltage was changed by one unit.
- FIG. 16 is a comparison before and after the correction of the APP669-711 / A ⁇ 1-42 ratio.
- the APP669-711 / A ⁇ 1-42 ratio has a small difference in intensity, and even before the correction, the variation between the three units and the variation when the detector voltage is changed by one unit are small. However, it was confirmed that the variation can be suppressed to be lower by performing the correction using the b value.
- Table 7 shows the CV of each A ⁇ peptide ratio calculated by classifying the data focusing on the b value.
- “Overall” is the CV calculated for all 6 condition measurements.
- “Change detector voltage in one aircraft” is a CV with three conditions acquired by changing the detector voltage in P1 unit.
- "Small variation in b value for 3 aircraft” is the CV obtained by the measurement result under the condition that the b value is close to 0.95 for 3 aircraft.
- “Large variation in b value for 3 aircraft” is the CV obtained from the measurement results under 3 conditions where the b value is different for 3 aircraft.
- the CV was originally low for "small variation in b value among the three aircraft", and there was no big difference before and after the correction, but in other cases, it can be seen that the CV was greatly reduced by the correction by the b value. This indicates that the correction by the b value is effective even when the device setting is changed between one unit or when the device state is different between different aircraft.
- Example 3 Adjustment of correction value b value 1
- the b value can be adjusted by the detector voltage. The following shows the results of investigating the relationship between the b value and the detector voltage.
- IC measurement was performed using normal A ⁇ 1-38 having the same ionization efficiency and SIL-A ⁇ 1-38 labeled with a stable isotope.
- ICs 1 to 5 the same ones used in 2-2 of Example 2 were used.
- FIG. 17 is a diagram showing the relationship between the detector voltage and the correction type b value. The vertical axis is the b value, and the horizontal axis is the detector voltage (V).
- FIG. 18 is a diagram showing the relationship between the detector voltage and the correction type b value. The vertical axis is the b value, and the horizontal axis is the detector voltage.
- the b value tends to decrease when the detector voltage is increased.
- the b value is 1.1 or more
- the b value changes by about 0.15 when the detector voltage is increased by 25 V
- the b value changes by about 0 when the detector voltage is increased by 25 V. It changed from 0.03 to 0.07.
- the detector voltage and the b value it is possible to increase the detector voltage and adjust the b value to a certain range when the b value rises due to deterioration of the detector or the like. ..
- the signal peak intensity ratio of the substance to be analyzed can be corrected more accurately.
- the range of the b value may be adjusted to 0.9 to 1.1.
- IC measurement was performed using normal A ⁇ 1-38 having the same ionization efficiency and SIL-A ⁇ 1-38 labeled with a stable isotope.
- ICs 1 to 5 the same ones used in 2-2 of Example 2 were used.
- FIG. 19 is a diagram showing the relationship between the detector voltage and the correction type b value.
- the vertical axis is the b value, and the horizontal axis is the detector voltage (V).
- the circled data points are the baseline setting 181 and the square data points are the baseline setting 179.
- the b value tends to decrease by lowering the baseline level setting.
- lowering the baseline setting by 2 lowers the b value by about 0.2 to 0.35, and when the b value is 1.1 or less, lowering the baseline setting by 2 causes b.
- the value decreased by about 0.15.
- the baseline setting of the AD converter Using the relationship between the baseline setting of the AD converter and the b value, it is possible to lower the baseline setting and adjust the b value to a certain range when the b value rises due to deterioration of the detector or the like. Is. By adjusting the b value to a certain range, the signal peak intensity ratio of the substance to be analyzed can be corrected more accurately.
- the range of the b value may be adjusted to 0.9 to 1.1.
- the present invention includes, for example, the following forms.
- a method for correcting the difference in signal intensity ratio in mass spectrometry including.
- x a reference signal peak intensity ratio or concentration ratio
- y a signal peak intensity ratio obtained in a mass spectrometer for which a correction formula should be obtained
- a is a coefficient in the approximate formula.
- b is a coefficient in the approximate expression and is a correction value
- a measurement method creation unit that creates a calibrant measurement method for calculating correction values in a mass spectrometer, and a measurement method creation unit.
- a correction value calculation unit that analyzes the mass spectrometry data acquired using the measurement method and calculates the correction value, The machine difference correction system of the mass spectrometer including.
- the measurement method creating unit includes a setting unit for setting a laser power value used for measuring the calibrant to a pre-calculated laser power value.
- the machine error correction system according to (14) or (15) above, which includes a sample plate display unit that displays a sample plate of the mass spectrometer.
- the sample plate display unit indicates a sample dropping position in the measurement method.
- the setting unit sets different laser power values for the sample well and the calibrator well.
- the machine difference correction system according to any one of (15) to (17) above.
- a measurement method creation step to create a measurement method for measuring a sample for calculating a correction value in a mass spectrometer, and a measurement method creation step.
- Mass spectrometry unit 2 Data processing unit 20 Measurement method creation unit 201 Setting unit 21 Correction value calculation unit 3 Input unit 4 Display unit
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
質量分析装置で、2つ以上のキャリブレーション物質を含むキャリブラントを測定して、前記キャリブレーション物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上のキャリブレーション物質のうちの1つのキャリブレーション物質のシグナルピークの強度に対する他のキャリブレーション物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記シグナルピーク強度比から補正式を求める工程と、
前記質量分析装置で、2つ以上の分析対象物質を含む試料を測定して、前記分析対象物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上の分析対象物質のうちの1つの分析対象物質のシグナルピークの強度に対する他の分析対象物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記補正式を用いて前記分析対象物質の前記シグナルピーク強度比を補正する工程と、
を含む質量分析におけるシグナル強度比の機差補正方法。
質量分析装置における補正値を算出するためのキャリブラントの測定メソッドを作成する測定メソッド作成部と、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出部と、
を含む質量分析装置の機差補正システム。
質量分析装置で、2つ以上のキャリブレーション物質を含むキャリブラントを測定して、前記キャリブレーション物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上のキャリブレーション物質のうちの1つのキャリブレーション物質のシグナルピークの強度に対する他のキャリブレーション物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記シグナルピーク強度比から補正式を求める工程と、
前記質量分析装置で、2つ以上の分析対象物質を含む試料を測定して、前記分析対象物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上の分析対象物質のうちの1つの分析対象物質のシグナルピークの強度に対する他の分析対象物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記補正式を用いて前記分析対象物質の前記シグナルピーク強度比を補正する工程と、
を含む。
分析対象物質は、特に限定されないが、例えば、ペプチド、糖ペプチド、糖鎖、タンパク質、脂質、糖脂質等が含まれ得る。ペプチド、糖ペプチド、糖鎖、タンパク質、脂質や糖脂質には種々のものが含まれ得る。より具体的には、Aβ及びAβ関連ペプチドであってもよい。「Aβ及びAβ関連ペプチド」は単に「Aβ関連ペプチド」と総称することもある。「Aβ及びAβ関連ペプチド」には、アミロイド前駆タンパク質(Amyloid precursor protein;APP)が切断されることにより生じるAβ及びAβの配列を一部でも含むペプチドが含まれる。実施例においては、Aβ及びAβ関連ペプチドを用いた例が示されている。
質量分析法は、特に限定されないが、マトリックス支援レーザー脱離イオン化(MALDI)質量分析法、エレクトロスプレーイオン化(ESI)質量分析法などによる質量分析法が含まれる。例えば、MALDI-TOF(マトリックス支援レーザー脱離イオン化-飛行時間)型質量分析装置、MALDI-IT(マトリックス支援レーザー脱離イオン化-イオントラップ)型質量分析装置、MALDI-IT-TOF(マトリックス支援レーザー脱離イオン化-イオントラップ-飛行時間)型質量分析装置、MALDI-FTICR(マトリックス支援レーザー脱離イオン化-フーリエ変換イオンサイクロトロン共鳴)型質量分析装置、ESI-QqQ(エレクトロスプレーイオン化-三連四重極)型質量分析装置、ESI-Qq-TOF(エレクトロスプレーイオン化-タンデム四重極-飛行時間)型質量分析装置、ESI-FTICR(エレクトロスプレーイオン化-フーリエ変換イオンサイクロトロン共鳴)型質量分析装置等を用いることができる。
本実施形態において、2つ以上のキャリブレーション物質を質量分析装置で測定する。前記キャリブレーション物質の測定結果を用いて、前記質量分析装置における補正式を算出する。
キャリブラントは、キャリブレーション物質を含む溶液である。本実施形態においては、キャリブラントは2つ以上のキャリブレーション物質を含む溶液である。
本実施形態において、2つ以上のキャリブレーション物質を質量分析装置で測定した結果を用いて、前記質量分析装置における補正式を算出する。そして、算出された補正式を用いて、分析対象物質の測定結果を補正する。本発明における補正の方法には、標準器との間の補正式を用いて補正する方法が含まれる。また、存在量が既知のキャリブレーション物質を用いて、質量分析における測定結果を規格化する方法が含まれる。
[5-1-1.補正式の算出]
標準器において、2つ以上のキャリブレーション物質を含むキャリブラント溶液を測定し、各キャリブレーション物質のシグナルピーク強度を得る。1つのキャリブレーション物質のシグナルピーク強度に対する、他のそれぞれのキャリブレーション物質のシグナルピーク強度の比をそれぞれ算出する。
直線回帰式(y=ax+b)
の補正係数a及びbを算出することができる。算出された直線回帰式(y=ax+b)を当該質量分析装置の補正式として用いることができる。
累乗回帰式(y=axb)
の補正係数a及びbを算出してもよい。算出された累乗回帰式(y=axb)を当該質量分析装置の補正式として用いることができる。
5-1-1.で補正式を算出した質量分析装置において、分析対象物質を含む試料を測定し、分析対象物質のシグナルピーク強度を得る。分析対象物質のうちの1つ(例えば、内部標準物質)を基準とし、その基準とする分析対象物質のシグナルピーク強度に対する、他の分析対象物質のシグナルピーク強度の比を算出する。
[5-2-1.補正式の算出]
2つのキャリブレーション物質の濃度比が既知の複数のキャリブラント溶液を用いて、シグナルピーク強度比を規格化する補正式を算出することができる。
直線回帰式(y=ax+b)
の補正係数a及びbを算出することができる。算出された直線回帰式(y=ax+b)を当該質量分析装置の補正式として用いることができる。
累乗回帰式(y=axb)
の補正係数a及びbを算出してもよい。算出された累乗回帰式(y=axb)を当該質量分析装置の補正式として用いることができる。
5-2-1.で補正式を算出した質量分析装置において、分析対象物質を含む試料を測定し、分析対象物質のシグナルピーク強度を得る。分析対象物質のうちの1つ(例えば、内部標準物質)を基準とし、その基準とする分析対象物質のシグナルピーク強度に対する、他の分析対象物質のシグナルピーク強度の比を算出する。
上述のとおり、本実施形態において、分析対象物質の測定に用いられる質量分析装置及びその装置条件において、補正式を算出し、補正を行うことにより、上述のとおり、質量分析装置の機体あるいは装置条件によらず、複数の試料間における分析対象物質の存在比を比較評価することが可能である。
本発明の一実施形態の質量分析装置の機差補正システムは、
質量分析装置における補正値を算出するためのキャリブラントの測定メソッドを作成する測定メソッド作成部と、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出部と、
を含む。
質量分析装置における補正値を算出するためのサンプルを測定する測定メソッドを作成する測定メソッド作成ステップと、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出ステップと、
を実行させることを含む。
[1-1 血漿中Aβ及びAβ関連ペプチドの測定]
本実施例において分析対象物質となるAβ及びAβ関連ペプチドは次のように調製した。
血漿サンプル(Sample 1)のIP-MSにより得られた内部標準ペプチド(SIL-Aβ1-38)に対するAβ、又はAβ関連ペプチドのピーク強度比を図1(A)に示した。同じサンプルに対して3台の同じ機種の質量分析装置(Performance 1~3)を用いて測定したが、ほとんどのAβ及びAβ関連ペプチドのピーク強度比は3台とも異なる結果であった。Aβ1-40の変動係数(CV)は48.7%で、Aβ1-42のCVは54.0%を示し、特に3台間の差が大きいことが確認された。一方、Aβ6-40のCVは3.8%を示し、3台間でほぼ同じ結果が得られていた。Aβ6-40はピーク強度比が1に近いが、Aβ1-40やAβ1-42はピーク強度比が1から離れている。このことから、ピーク強度比が1に近いほど3台間の差が小さく、1から離れるほど(つまり、1よりも小さくなる、又は1よりも大きくなるほど)3台間の差が大きくなる傾向があることが示唆された。
y=1.282x+0.045
ここで、xは、Performance 2におけるシグナルピーク強度比を対数変換した値であり、yは、Performance 1におけるシグナルピーク強度比を対数変換した値である。
y=1.981x+0.081
ここで、xは、Performance 3におけるシグナルピーク強度比を対数変換した値であり、yは、Performance 1におけるシグナルピーク強度比を対数変換した値である。
y=1.108x1.282
ここで、xは、Performance 2におけるシグナルピーク強度比の値であり、yは、Performance 1におけるシグナルピーク強度比の値である。
y=1.204x1.981
ここで、xは、Performance 3におけるシグナルピーク強度比の値であり、yは、Performance 1におけるシグナルピーク強度比の値である。
1-2で作成された補正式が他のサンプルでも適用可能かどうかを調べるために、上述の1-1で用いたサンプルとは異なる血漿サンプル(Sample No.2及びNo.3)に対してIP-MSを行い、補正前と後のピーク強度比を比較した。IP-MSは1-1と同じ方法で実施し、補正式は1-2において算出した、ピーク強度比の対数変換値に対する直線回帰式を用いた。その結果、Sample No.2とNo.3ともに、補正することにより3台間で同等のピーク強度比を得られることが確認された(図6、7)。機体によっては検出感度が足りないペプチドもあり、その場合の検出限界以下のデータに関してはND(Not detectable)と示している。
1-2で作成された補正式の再現性を検証することにした。1-1と異なる日に、1-1と同様の手順でIP-MSを実施し、補正式(対数変換値に対する直線回帰式)を作成した(図8、9)。1-1を実施した日をDay1とし、新たに補正用回帰式(対数変換値に対する直線回帰式)を作成した日をDay2と呼ぶ。Day1及びDay2で得られた各機体間の補正式は表2の通りである。
Performance 2(Day1) vs Performance 3(Day1)と
Performance 2(Day2) vs Performance 3(Day2)
の二つの比較では回帰式が異なることが証明され、
Performance 2(Day1) vs Performance 2(Day2)と
Performance 3(Day1) vs Performance 3(Day2)
の2つの比較では回帰式が同じことが証明された。これらの結果は、補正式が機体によって固有の回帰式が存在しており、検出器の劣化等により装置の状態が変化しない限り、回帰式は測定した日にちによって変動しないことを示している。
[2-1 血漿中Aβ及びAβ関連ペプチドの測定]
本実施例において分析対象物質となるAβ及びAβ関連ペプチドは次のように調製した。
IP-MSで取得したSIL-Aβ1-38に対する各Aβ及びAβ関連ペプチドのピーク強度比を補正するための強度比キャリブラント(Intensity ratio Calibrant; IC)試薬の濃縮液5種類を表4の組成で調製し、冷凍保存した。MS測定前に、IC-1~5濃縮液を解凍し、2-1の2nd IP溶出液(5mM HCl,0.1mM Methionine,70%(v/v)アセトニトリル)で10倍希釈してIC-1~5を調製し、予め0.5mg/mL CHCA/0.2%(w/v)MDPNA 0.5μLを滴下、乾燥させたμFocus MALDI plateTM900μm上へ、IC-1~5を1μLずつ4ウェルに滴下して乾燥させた。IC-1~5のタンパク質・ペプチド組成を表5に示す。IC-1~5におけるSIL-Aβ1-38に対するAβ1-38の量比は、それぞれ4,2,1,1/2,1/4とした。
検出器の交換前後のPerformance 1号機、及びPerformance 3号機の3条件において、ヒト血漿のIP-MS及びIC-1~5測定を実施した。
ここで、xは、Aβ1-38/SIL-Aβ1-38の量比、yは、Aβ1-38/SIL-Aβ1-38のピーク強度比であり、a及びbは近似式における係数である。
y=1.0032x1.0402
y=1.0413x0.8182
y=1.0353x0.7714
標準血漿に3種のAβペプチド(Aβ1-40、Aβ1-42、及びAPP669-766)及び内部標準ペプチドをスパイクしたサンプルをIP処理し、3台のAXIMA-PerformanceでIC試薬とともに測定を行った。測定した機体と検出器電圧、及び、IC測定の結果から算出されたb値は表6の通りであった。
「1機体内で検出器電圧変更」は、P1号機で検出器電圧を変更して取得した三条件のCV
「3機体でb値のばらつき小」は、3機体でb値が0.95に近い条件の測定結果で出したCV
「3機体でb値のばらつき大」は、3機体でb値がバラバラの3条件での測定結果で出したCV
実施例2の2-4に記載のとおり、b値と検出器電圧に相関があるため、b値を検出器電圧で調整することができる。以下に、b値と検出器電圧の関係を調べた結果を示す。
b値を調製する別の手段として、アナログ-デジタル変換器(ADコンバータ)のベースラインレベルの調整があげられる。以下に、b値とADコンバータのベースラインレベル設定、およびの検出器電圧の関係を調べた結果を示す。
質量分析装置で、2つ以上のキャリブレーション物質を含むキャリブラントを測定して、前記キャリブレーション物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上のキャリブレーション物質のうちの1つのキャリブレーション物質のシグナルピークの強度に対する他のキャリブレーション物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記シグナルピーク強度比から補正式を求める工程と、
前記質量分析装置で、2つ以上の分析対象物質を含む試料を測定して、前記分析対象物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上の分析対象物質のうちの1つの分析対象物質のシグナルピークの強度に対する他の分析対象物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記補正式を用いて前記分析対象物質の前記シグナルピーク強度比を補正する工程と、
を含む質量分析におけるシグナル強度比の機差補正方法。
前記キャリブレーション物質が、安定同位体標識された物質と、安定同位体標識されていない物質とを含む、上記(1)に記載の補正方法。
前記分析対象物質が、ペプチド、糖ペプチド、糖鎖、脂質、及び糖脂質からなる群に属する物質から選ばれる、上記(1)又は(2)に記載の補正方法。
前記キャリブレーション物質が、Aβ関連ペプチドである、上記(1)~(3)のいずれかに記載の補正方法。
前記キャリブレーション物質が、Aβ1-38と、安定同位体標識されたAβ1-38である、上記(1)~(4)のいずれかに記載の補正方法。
前記キャリブラントが、3種類以上のキャリブレーション物質を含む、上記(1)~(5)のいずれかに記載の補正方法。
前記キャリブラントが、複数であり、
複数の前記キャリブラントは、前記シグナルピーク強度比を求めるべき前記キャリブレーション物質のうち少なくとも1つのキャリブレーション物質の濃度がそれぞれ異なる、上記(1)~(6)のいずれかに記載の補正方法。
1つのキャリブレーション物質の濃度に対する他のキャリブレーション物質の濃度の比が、1/4~4の範囲である、上記(7)に記載の補正方法。
前記補正式を求める工程において、前記シグナルピーク強度比を対数変換した値を用いて補正式を求める、上記(1)~(8)のいずれかに記載の補正方法。
前記補正式が、線形、多項式、指数、対数、又は累乗の補正式である、上記(1)~(9)のいずれかにに記載の補正方法。
前記補正式における係数が所定の値の範囲である、上記(1)~(10)のいずれかに記載の補正方法。
前記補正式における前記係数は、前記質量分析装置の検出器電圧及び/又はADコンバータのベースラインレベルを調整することにより、前記所定の値の範囲に調整される、上記(11)に記載の補正方法。
前記補正式が、累乗近似式:
y=axb
(ここで、xは、基準となるシグナルピーク強度比、又は濃度比であり、yは、補正式を求めるべき質量分析装置において得られたシグナルピーク強度比であり、aは、近似式における係数であり、bは、近似式における係数であり、かつ、補正値である)
で表される、上記(1)~(12)のいずれかに記載の補正方法。
質量分析装置における補正値を算出するためのキャリブラントの測定メソッドを作成する測定メソッド作成部と、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出部と、
を含む質量分析装置の機差補正システム。
前記測定メソッド作成部が、前記キャリブラントの測定に用いられるレーザーパワー値を予め算出されたレーザーパワー値に設定する設定部を含む、上記(14)に記載の機差補正システム。
前記質量分析装置のサンプルプレートを表示するサンプルプレート表示部を含む、上記(14)又は(15)に記載の機差補正システム。
前記サンプルプレート表示部は、前記測定メソッドにおけるサンプル滴下位置を示す、
上記(16)に記載の機差補正システム。
前記設定部は、サンプルウェルとキャリブラントウェルにそれぞれ異なるレーザーパワー値を設定する、
上記(15)~(17)のいずれかに記載の機差補正システム。
コンピュータに、
質量分析装置における補正値を算出するためのサンプルを測定する測定メソッドを作成する測定メソッド作成ステップと、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出ステップと、
を実行させることを含む質量分析装置の機差補正用プログラム。
2 データ処理部
20 測定メソッド作成部
201 設定部
21 補正値算出部
3 入力部
4 表示部
Claims (19)
- 質量分析装置で、2つ以上のキャリブレーション物質を含むキャリブラントを測定して、前記キャリブレーション物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上のキャリブレーション物質のうちの1つのキャリブレーション物質のシグナルピークの強度に対する他のキャリブレーション物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記シグナルピーク強度比から補正式を求める工程と、
前記質量分析装置で、2つ以上の分析対象物質を含む試料を測定して、前記分析対象物質のそれぞれのシグナルピークを得る工程と、
前記2つ以上の分析対象物質のうちの1つの分析対象物質のシグナルピークの強度に対する他の分析対象物質のシグナルピークの強度のシグナルピーク強度比を求める工程と、
前記補正式を用いて前記分析対象物質の前記シグナルピーク強度比を補正する工程と、
を含む質量分析におけるシグナル強度比の機差補正方法。 - 前記キャリブレーション物質が、安定同位体標識された物質と、安定同位体標識されていない物質とを含む、請求項1に記載の補正方法。
- 前記分析対象物質が、ペプチド、糖ペプチド、糖鎖、脂質、及び糖脂質からなる群に属する物質から選ばれる、請求項1に記載の補正方法。
- 前記キャリブレーション物質が、Aβ関連ペプチドである、請求項1に記載の補正方法。
- 前記キャリブレーション物質が、Aβ1-38と、安定同位体標識されたAβ1-38である、請求項1に記載の補正方法。
- 前記キャリブラントが、3種類以上のキャリブレーション物質を含む、請求項1に記載の補正方法。
- 前記キャリブラントが、複数であり、
複数の前記キャリブラントは、前記シグナルピーク強度比を求めるべき前記キャリブレーション物質のうち少なくとも1つのキャリブレーション物質の濃度がそれぞれ異なる、請求項1に記載の補正方法。 - 1つのキャリブレーション物質の濃度に対する他のキャリブレーション物質の濃度の比が、1/4~4の範囲である、請求項7に記載の補正方法。
- 前記補正式を求める工程において、前記シグナルピーク強度比を対数変換した値を用いて補正式を求める、請求項1に記載の補正方法。
- 前記補正式が、線形、多項式、指数、対数、又は累乗の補正式である、請求項1に記載の補正方法。
- 前記補正式における係数が所定の値の範囲である、請求項1に記載の補正方法。
- 前記補正式における前記係数は、前記質量分析装置の検出器電圧及び/又はADコンバータのベースラインレベルを調整することにより、前記所定の値の範囲に調整される、請求項11に記載の補正方法。
- 前記補正式が、累乗近似式:
y=axb
(ここで、xは、基準となるシグナルピーク強度比、又は濃度比であり、yは、補正式を求めるべき質量分析装置において得られたシグナルピーク強度比であり、aは、近似式における係数であり、bは、近似式における係数であり、かつ、補正値である)
で表される、請求項1に記載の補正方法。 - 質量分析装置における補正値を算出するためのキャリブラントの測定メソッドを作成する測定メソッド作成部と、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出部と、
を含む質量分析装置の機差補正システム。 - 前記測定メソッド作成部が、前記キャリブラントの測定に用いられるレーザーパワー値を予め算出されたレーザーパワー値に設定する設定部を含む、請求項14に記載の機差補正システム。
- 前記質量分析装置のサンプルプレートを表示するサンプルプレート表示部を含む、請求項14に記載の機差補正システム。
- 前記サンプルプレート表示部は、前記測定メソッドにおけるサンプル滴下位置を示す、
請求項16に記載の機差補正システム。 - 前記設定部は、サンプルウェルとキャリブラントウェルにそれぞれ異なるレーザーパワー値を設定する、請求項15に記載の機差補正システム。
- コンピュータに、
質量分析装置における補正値を算出するためのサンプルを測定する測定メソッドを作成する測定メソッド作成ステップと、
前記測定メソッドを用いて取得した質量分析データを解析して補正値を算出する補正値算出ステップと、
を実行させることを含む質量分析装置の機差補正用プログラム。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180056975.4A CN116157894A (zh) | 2020-08-07 | 2021-01-06 | 质谱分析装置的机差校正方法 |
EP21852833.9A EP4195237A1 (en) | 2020-08-07 | 2021-01-06 | Machine difference correction method for mass spectrometry apparatus |
JP2022541108A JP7364086B2 (ja) | 2020-08-07 | 2021-01-06 | 質量分析装置の機差補正方法 |
US18/019,626 US20240266158A1 (en) | 2020-08-07 | 2021-01-06 | Machine Difference Corrrection Method for Mass Spectrometry Apparatus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063062677P | 2020-08-07 | 2020-08-07 | |
US63/062,677 | 2020-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022030032A1 true WO2022030032A1 (ja) | 2022-02-10 |
Family
ID=80117212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/000235 WO2022030032A1 (ja) | 2020-08-07 | 2021-01-06 | 質量分析装置の機差補正方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240266158A1 (ja) |
EP (1) | EP4195237A1 (ja) |
JP (1) | JP7364086B2 (ja) |
CN (1) | CN116157894A (ja) |
WO (1) | WO2022030032A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1010049A (ja) * | 1996-06-19 | 1998-01-16 | Olympus Optical Co Ltd | 分析方法 |
JP2007503001A (ja) * | 2003-05-15 | 2007-02-15 | エレクトロフォレティクス リミテッド | 質量分析法 |
WO2015178398A1 (ja) | 2014-05-22 | 2015-11-26 | 株式会社 島津製作所 | 脳内のアミロイドβペプチド蓄積状態を評価するサロゲート・バイオマーカー及びその分析方法 |
WO2017047529A1 (ja) | 2015-09-16 | 2017-03-23 | 株式会社 島津製作所 | 脳内のアミロイドβ蓄積状態を評価するマルチプレックスバイオマーカー及びその分析方法 |
JP2017102100A (ja) * | 2015-11-20 | 2017-06-08 | 株式会社日立ハイテクサイエンス | 発生ガス分析方法及び発生ガス分析装置 |
JP2020511671A (ja) * | 2017-02-24 | 2020-04-16 | アイロア テクノロジーズ リミテッド ライアビリティ カンパニー | 改善された精度、同定および定量化のためのiroaメタボロミクスワークフロー |
-
2021
- 2021-01-06 CN CN202180056975.4A patent/CN116157894A/zh active Pending
- 2021-01-06 US US18/019,626 patent/US20240266158A1/en active Pending
- 2021-01-06 EP EP21852833.9A patent/EP4195237A1/en active Pending
- 2021-01-06 WO PCT/JP2021/000235 patent/WO2022030032A1/ja active Application Filing
- 2021-01-06 JP JP2022541108A patent/JP7364086B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1010049A (ja) * | 1996-06-19 | 1998-01-16 | Olympus Optical Co Ltd | 分析方法 |
JP2007503001A (ja) * | 2003-05-15 | 2007-02-15 | エレクトロフォレティクス リミテッド | 質量分析法 |
WO2015178398A1 (ja) | 2014-05-22 | 2015-11-26 | 株式会社 島津製作所 | 脳内のアミロイドβペプチド蓄積状態を評価するサロゲート・バイオマーカー及びその分析方法 |
US20170184573A1 (en) | 2014-05-22 | 2017-06-29 | Shimadzu Corporation | SURROGATE BIOMARKER FOR EVALUATING INTRACEREBRAL AMYLOID ß PEPTIDE ACCUMULATION AND METHOD FOR ANALYSIS THEREOF |
WO2017047529A1 (ja) | 2015-09-16 | 2017-03-23 | 株式会社 島津製作所 | 脳内のアミロイドβ蓄積状態を評価するマルチプレックスバイオマーカー及びその分析方法 |
US20180238909A1 (en) | 2015-09-16 | 2018-08-23 | Shimadzu Corporation | Multiplex biomarker for use in evaluation of state of accumulation of amyloid b in brain, and analysis method for said evaluation |
JP2017102100A (ja) * | 2015-11-20 | 2017-06-08 | 株式会社日立ハイテクサイエンス | 発生ガス分析方法及び発生ガス分析装置 |
JP2020511671A (ja) * | 2017-02-24 | 2020-04-16 | アイロア テクノロジーズ リミテッド ライアビリティ カンパニー | 改善された精度、同定および定量化のためのiroaメタボロミクスワークフロー |
Non-Patent Citations (5)
Title |
---|
HAN DKENG JZHOU HAEBERSOLD R: "Quantitative profiling of differentiationinduced microsomal proteins using isotope-coded affinity tags and mass spectrometry", NAT BIOTECHNOL., vol. 19, no. 10, October 2001 (2001-10-01), pages 946 - 51, XP002959184, DOI: 10.1038/nbt1001-946 |
KANEKO NNAKAMURA AWASHIMI YKATO TSAKURAI TARAHATA YBUNDO MTAKEDA ANIIDA SITO K: "Novel plasma biomarker surrogating cerebral amyloid deposition", PROC JPN ACAD SER B PHYS BIOL SCI, vol. 90, no. 9, 2014, pages 353 - 364, XP055238351, DOI: 10.2183/pjab.90.353 |
NAKAMURA AKANEKO NVILLEMAGNE VLKATO TDOECKE JDORE VFOWLER CLI QXMARTINS RROWE C: "High performance plasma amyloid-(3 biomarkers for Alzheimer's disease", NATURE, vol. 554, no. 7691, 2018, pages 249 - 254, XP055618943, DOI: 10.1038/nature25456 |
NICOL GRHAN MKIM JBIRSE CEBRAND ENGUYEN AMESRI MFITZHUGH WKAMINKER PMOORE PA: "Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients", MOL CELL PROTEOMICS, vol. 7, no. 10, October 2008 (2008-10-01), pages 1974 - 82, XP002581971, DOI: 10.1074/MCP.M700476-MCP200 |
ROSS PLHUANG YNMARCHESE JNWILLIAMSON BPARKER KHATTAN SKHAINOVSKI NPILLAI SDEY SDANIELS S: "Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents", MOL CELL PROTEOMICS, vol. 3, no. 12, December 2004 (2004-12-01), pages 1154 - 69, XP055533176, DOI: 10.1074/mcp.M400129-MCP200 |
Also Published As
Publication number | Publication date |
---|---|
EP4195237A1 (en) | 2023-06-14 |
CN116157894A (zh) | 2023-05-23 |
US20240266158A1 (en) | 2024-08-08 |
JPWO2022030032A1 (ja) | 2022-02-10 |
JP7364086B2 (ja) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8373115B2 (en) | Method and apparatus for identifying proteins in mixtures | |
Taban et al. | Imaging of peptides in the rat brain using MALDI-FTICR mass spectrometry | |
Gallien et al. | Selected reaction monitoring applied to proteomics | |
JP5199101B2 (ja) | 生体分子の検定を開発するための方法 | |
Cox et al. | Computational principles of determining and improving mass precision and accuracy for proteome measurements in an Orbitrap | |
EP2909618B1 (en) | Accurate and interference-free multiplexed quantitative proteomics using mass spectrometry | |
JP2007535673A (ja) | 質量分析計 | |
JP2009516842A (ja) | 質量分析計 | |
Nicolardi et al. | Precision profiling and identification of human serum peptides using Fourier transform ion cyclotron resonance mass spectrometry | |
Lin et al. | Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine | |
US6498340B2 (en) | Method for calibrating mass spectrometers | |
EP4033250A1 (en) | Method of assaying the purity of a therapeutic polypeptide | |
Couto et al. | Application of the broadband collision‐induced dissociation (bbCID) mass spectrometry approach for protein glycosylation and phosphorylation analysis | |
WO2022176612A1 (ja) | 質量分析装置で用いられるキャリブラント及びその作製方法 | |
WO2022030032A1 (ja) | 質量分析装置の機差補正方法 | |
Sandoval | Matrix‐assisted laser desorption/ionization time‐of‐flight mass analysis of peptides | |
EP4312027A1 (en) | Quality control standard solution used in peptide assay, and quality control of peptide assay | |
WO2022215341A1 (ja) | 検量線の作成方法およびアミロイドβ関連ペプチドの測定方法 | |
JP2021025946A (ja) | 糖ペプチド解析装置 | |
Jing et al. | An improved calibration method for the matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resononance analysis of 15N-metabolically-labeled proteome digests using a mass difference approach | |
Dusberger | Improving the protein identification performance in high-resolution mass spectrometry data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21852833 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022541108 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18019626 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021852833 Country of ref document: EP Effective date: 20230307 |